Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Stephens

Showing results (51-60 of 168) with videos related to

Pageof 17
Sort By:
The Oncologist|September 30, 2016
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal CancerAndrew Rankin, Samuel J Klempner, Rachel Erlich, et al.
Breast Cancer Research and Treatment|October 14, 2015
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Siraj M Ali, Kai Wang, et al.
Clinical Breast Cancer|November 9, 2013
Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinibSiraj M Ali, R Kathy Alpaugh, Jamie K Buell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancerNir Peled, Gary Palmer, Fred R Hirsch, et al.
Archives of Pathology & Laboratory Medicine|May 1, 2015
Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment optionsJeffrey S Ross, Sunil Badve, Kai Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From GangliogliomaSilviya K Meletath, Dean Pavlick, Tim Brennan, et al.
Pediatric Blood & Cancer|January 19, 2017
Identification of NTRK fusions in pediatric mesenchymal tumorsDean Pavlick, Alexa B Schrock, Denise Malicki, et al.
British Journal of Haematology|June 14, 2016
Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targetsAdrienne Johnson, Deborah Morosini, Jo-Anne Vergilio, et al.
The Oncologist|September 4, 2015
Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and DifferencesKai Wang, Adrienne Johnson, Siraj M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2013
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibitionKatherine E Hutchinson, Doron Lipson, Philip J Stephens, et al.
Pageof 17

Showing results (51-60 of 168) with videos related to

Sort By:
Pageof 17
The Oncologist|September 30, 2016
Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal CancerAndrew Rankin, Samuel J Klempner, Rachel Erlich, et al.
Breast Cancer Research and Treatment|October 14, 2015
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterationsJeffrey S Ross, Siraj M Ali, Kai Wang, et al.
Clinical Breast Cancer|November 9, 2013
Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinibSiraj M Ali, R Kathy Alpaugh, Jamie K Buell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancerNir Peled, Gary Palmer, Fred R Hirsch, et al.
Archives of Pathology & Laboratory Medicine|May 1, 2015
Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment optionsJeffrey S Ross, Sunil Badve, Kai Wang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From GangliogliomaSilviya K Meletath, Dean Pavlick, Tim Brennan, et al.
Pediatric Blood & Cancer|January 19, 2017
Identification of NTRK fusions in pediatric mesenchymal tumorsDean Pavlick, Alexa B Schrock, Denise Malicki, et al.
British Journal of Haematology|June 14, 2016
Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targetsAdrienne Johnson, Deborah Morosini, Jo-Anne Vergilio, et al.
The Oncologist|September 4, 2015
Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and DifferencesKai Wang, Adrienne Johnson, Siraj M Ali, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2013
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibitionKatherine E Hutchinson, Doron Lipson, Philip J Stephens, et al.
Pageof 17